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Abstract Assess the sensitivity of the Magnetic Reso-
nance Disease Severity Scale (MRDSS), based on cerebral
lesions and atrophy, for treatment monitoring of glatiramer
acetate (GA) in relapsing-remitting multiple sclerosis
(MS). This retrospective non-randomized pilot study
included patients who started daily GA [n = 23, age
(median, range) 41 (26.2, 53.1) years, Expanded Disability
Status Scale (EDSS) score 1.0 (0, 3.5)], or received no
disease-modifying therapy (noDMT) [n = 21, age 44.8
(28.2, 55.4), EDSS 0 (0, 2.5)] for 2 years. MRDSS was the
sum of z-scores (normalized to a reference sample) of T2
hyperintense lesion volume (T2LV), the ratio of T1
hypointense LV to T2LV (T1/T2), and brain parenchymal
fraction (BPF) multiplied by negative 1. The two groups
were compared by Wilcoxon rank sum tests; within group
change was assessed by Wilcoxon signed rank tests.
Glatiramer acetate subjects had less progression than
noDMT on T1/T2 [(median z-score change (range), 0
(-1.07, 1.20) vs. 0.41 (-0.30, 2.51), p = 0.003)] and
MRDSS [0.01 (-1.33, 1.28) vs. 0.46 (-1.57, 2.46),
p = 0.01]; however, not on BPF [0.12 (-0.18, 0.58) vs.
0.10 (-1.47,0.50), p = 0.59] and T2LV [-0.03 (-0.90,
0.57) vs. 0.01 (-1.69, 0.34), p = 0.40]. While GA subjects
worsened only on BPF [0.12 (-0.18, 0.58), p = 0.001],
noDMT worsened on BPF [0.10 (-1.47, 0.50), p = 0.002],
T1/T2 [0.41 (-0.30, 2.51), p = 0.0002], and MRDSS [0.46
(-1.57, 2.46), p = 0.0006]. These preliminary findings
show the potential of two new cerebral MRI metrics to
track MS therapeutic response. The T1/T2, an index of the
destructive potential of lesions, may provide particular
sensitivity to treatment effects.
Keywords MRI Multiple sclerosis  Glatiramer acetate 
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Introduction
MRI has provided a range of tools to define pathological
changes in the brain and spinal cord in patients with mul-
tiple sclerosis (MS) [1]. Prior studies have combined
cerebral MRI lesion and atrophy measures to create com-
posite scales to increase sensitivity, provide a compre-
hensive assessment of disease status, and, in turn, provide
more clinical relevance than individual MRI measures on
their own [2–11]. The first such measure, the Z4 score,
combined measures of disease activity and disease severity,
and has been applied to assess treatment response [2, 4, 8].
These MS-MRI composite scales have shown higher effect
sizes in their relationship to clinical status or longitudinal
change as compared to established individual MS-MRI
measures [5–7, 11, 12]. Building on this previous work, we
tested a cerebral MRI composite scale focusing on MS
disease severity as shown by lesions and atrophy which
also includes an assessment of the destructive potential of
individual lesions, the intrasubject ratio of T1 hypointense
to T2 hyperintense lesion volume (T1/T2). Known as the
Magnetic Resonance Disease Severity Scale (MRDSS) [5],
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this tool has shown higher effect sizes in differentiating
relapsing-remitting (RR) from secondary progressive (SP)
patients and higher longitudinal sensitivity than the com-
ponent MRI measures on their own [5, 7]. To date, the role
of the MRDSS in treatment monitoring has not been tested.
Glatiramer acetate (GA) is an established disease-mod-
ifying therapy (DMT) for RRMS [13–16]. GA is known to
effectively reduce relapse rates and the appearance of new
gadolinium (Gd)-enhancing and T2 hyperintense lesions
[16]. In addition, GA limits the progression of destructive
aspects of the disease including the rate of brain atrophy
[17] and the evolution of new Gd-enhancing lesions con-
verting to chronic T1 hypointensities (‘‘black holes’’) [18].
The goal of the present pilot study was to evaluate the
2-year longitudinal sensitivity of the MRDSS in comparing
GA-treated to untreated patients with RRMS. Furthermore,
this study provided the unique opportunity to assess the
role of T1/T2 in tracking therapeutic response.
Methods
Subjects
Baseline demographic and clinical characteristics are
summarized in Table 1. This was a retrospective non-ran-
domized two-arm observational exploratory study. Given
the sample size and study design, the results should be
considered preliminary. All subjects were identified by
chart review using the following inclusion criteria: RRMS
[19], age 18–55, and an Expanded Disability Status Scale
(EDSS) [20] score 0–5. Among the 44 patients with
RRMS, two groups were identified based on DMT use
during the 2-year observation period: (1) GA-treated
(n = 23) and (2) no DMT (noDMT, n = 21), i.e. patients
who remained off DMT. Patients were required to have a
baseline and 2-year brain MRI available. Clinical evalu-
ation, including EDSS scoring [20] and timed 25 foot
walk (T25FW) [21], were assessed by the treating neu-
rologist at the Partners MS Center. When comparing
groups on baseline clinical and demographic characteris-
tics, the noDMT group showed a trend to a higher per-
centage of women (p = 0.07) and higher age (p = 0.09),
and a significantly higher disease duration (p = 0.008)
and lower EDSS score (p = 0.048). This study was
approved by our institution’s research ethics committee
and was performed in accordance with the ethical stan-
dards laid down in the 1964 Declaration of Helsinki and
its later amendments.
MRI acquisition
All patients underwent baseline and follow-up 1.5 T brain
MRI on a fleet of Signa scanners (General Electric, Mil-
waukee, WI) at our institution. All scans covered the whole
brain in the axial plane and included T1-weighted spin-
echo [repetition time and echo time (TR/TE): 550–783/
20 ms] and T2-weighted conventional spin-echo dual-echo
series (TR/TE1/TE2: 2750–3000/30/80 ms), with voxel
sizes of either 0.9375 9 0.9375 9 3 mm or 0.8594 9
0.8594 9 3 mm, and no inter-slice gaps. The T1-weighted
series was repeated 5–7 min after the intravenous infusion
of single-dose Gd. MRI analysis was performed by
observers who were unaware of the clinical details.
Table 1 Subjects’
characteristics and clinical
findings at baseline and 2-year
follow-up
Glatiramer acetate NoDMT p value
Baseline
Number of patients n = 23 n = 21 –
Women, number (%) 15 (65) 19 (90) 0.07
Age (years) 41.3 (26.2, 53.1) 44.8 (28.2, 55.4) 0.09
Disease durationa (years) 1.8 (0.3, 20.3) 6.5 (0.4, 33.5) 0.008
EDSS score 1.0 (0, 3.5) 0 (0, 2.5) 0.048
T25FW (s) 4.2 (3.0, 5.6) 5.0 (3.4, 6.0) 0.32
Follow-up
EDSS score 1.0 (0, 3.0) 0 (0, 2.0) 0.39
T25FW (s) 4.2 (2.7, 6.0) 4.5 (3.5, 5.7) 0.07
On-study annualized relapse rate (mean) 0.13 0.12 0.88
Key: values are median (range), unless otherwise indicated
The p value for women—Fisher’s exact test, for on-study relapses—Poisson regression, and the other
p values—Wilcoxon rank sum tests
NoDMT not receiving disease-modifying therapy, RRMS relapsing-remitting multiple sclerosis, EDSS
Expanded Disability Status Scale, T25FW timed 25 foot walk
a Time since first symptoms
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MRI analysis
T2 hyperintense lesion volume and whole brain atrophy
Using the dual-echo T2-weighted images, the T2 hyper-
intense lesion volume (T2LV) and the normalized whole
brain volume (brain parenchymal fraction—BPF) were
calculated by an automated template-driven segmentation
(TDS?) [22].
T1 hypointense lesion volume/T2 hyperintense lesion
volume ratio
T1 hypointense lesions were initially identified and traced
by a trained observer using a semi-automated edge-find-
ing tool in Jim software (v.7; Xinapse Systems, West
Bergholt, UK; http://www.xinapse.com). Each lesion and
its contour was then confirmed by an experienced obser-
ver. T1 hypointense lesions were defined as appearing
hypointense to the surrounding white matter, with corre-
sponding hyperintensity on both of the dual-echo images.
The lesions were also required to show non-enhancement
on post-Gd images. To assess the destructive potential of
lesions, the ratio of the T1 hypointense lesion volume to
the T2LV (T1/T2) was calculated for each patient. This
was used in favor of the total T1 hypointense lesion
volume (T1LV) based on our previous work showing high
co-linearity between T1LV and T2LV [5].
Calculation of MRDSS
Magnetic Resonance Disease Severity Scale was derived
by calculating z-scores for appropriate transformations of
each component as in the original paper [5], and the mean
and standard deviation used in the z-score calculation were
the values from the original paper to ensure that these were
representative of a typical clinic-based MS population [5].
For the BPF, no transformation was required, but the z-
score was multiplied by -1 so that higher values of -zBPF
represented lower BPF and worse disease severity. For
T2LV, a log transformation was used, and the z-score was
referred to as zT2LV. Finally, for the T1/T2, the logistic
transformation was used, and the z-score was named zT1/
T2. Subjects with T1/T2 of 0 were assigned a value more
extreme (zT1/T2 = -2.5) than the smallest observed value
(zT1/T2 = -1.96). We note that all values for T1/T2 and
T2LV were rounded to two decimal places. To combine the
z-scores, the following equation was used:
zMRDSS ¼ zBPFþ zT2LV þ zT1=T2
The zMRDSS was not rescaled to lie between 0 and 10
as in the original paper because observations in the present
sample would have been outside of this range. Rather, the
zMRDSS score was used for analysis. For simplicity pur-
poses, the zMRDSS is referred to often as MRDSS
throughout the remaining sections of the paper. This ver-
sion of the MRDSS has been referred to as ‘‘MRDSS1’’ in
a subsequent paper [10].
Statistical analysis
In order to compare the GA treated subjects to the
untreated subjects in terms of MRI measures at baseline,
year 2 and on-study changes in MRI measures, Wilcoxon
rank sum tests were performed. To determine if there
were within group changes in MRI measures over time,
Wilcoxon signed rank tests were used. For clinical out-
comes, the EDSS and T25FW in each group were com-
pared at baseline and year 2 using a Wilcoxon rank sum
test. To compare the groups on changes over time in
clinical outcomes, a mixed effects ordinal logistic
regression model was used. Finally, to compare the
number of on-study relapses, a Poisson regression model
was used. A p\ 0.05 was considered significant; a
p[ 0.05 but \0.10 was considered a trend to signifi-
cance. All statistical analysis was completed in the sta-
tistical package R (http://www.r-project.org) or Stata
(version 14).
Results
Baseline and follow-up MRI differences in the GA
and noDMT groups
When evaluating the MRI differences between the GA and
noDMT groups at baseline and follow-up, no significant
differences were found (Table 2). Only the T1/T2 differ-
ence at follow-up showed a trend towards significance
(lower in the GA group).
On-study changes in MRI measures in the GA
and noDMT groups
When comparing the 2-year on-study changes in MRI
measures between the GA and noDMT groups (Table 3;
Figs. 1, 2, 3, 4), subjects in the GA group had significantly
less worsening of disease over the 2-year follow-up in
terms of T1/T2 (Fig. 3) and MRDSS (Fig. 4). Considering
the on-study changes within the GA cohort, a significant
worsening was only seen in BPF [0.12 (-0.18, 0.58),
p = 0.001). However, when assessing the on-study chan-
ges within the noDMT group, statistically significant
worsening was seen in BPF [0.01 (-1.47, 0.50),
p = 0.002], T1/T2 [0.41 (-0.30, 2.51), p = 0.0002], and
MRDSS [0.46 (-1.57, 2.46), p = 0.0006]. Because the
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p value for the group comparison for the difference was
more statistically significant for the T1/T2 than the other
individual MRI components, this implies that the differ-
ence between treatment groups in MRDSS was driven by
the T1/T2 change. This was confirmed by the observations
in Table 3 that there was only a limited group difference in
the change for the BPF or T2LV.
On-study clinical changes/relapses
On-study and follow-up clinical changes/relapse data are
shown in Table 1. When comparing the groups in terms of
on-study EDSS and T25FW change, a mixed effects ordi-
nal regression model determined that there was no signif-
icant group difference in terms of change over time
(p = 0.29 and p = 0.35, respectively). At follow-up, there
was no difference between groups in EDSS score
(p = 0.39). At follow-up, the T25FW trended to being
lower in the GA vs. the noDMT group (p = 0.07). Patients
in the GA group had an average of 0.26 clinical relapses
over the 2 years (mean annualized attack rate = 0.13).
This was 0.24 (mean annualized attack rate = 0.12) in the
noDMT group. A Poisson regression model determined
that there was no significant difference between the groups
in terms of on-study relapses (p = 0.88).
Discussion
In this pilot study, we explored the use of a cerebral MRI-
based composite scale of disease severity, based on lesions
and atrophy, the MRDSS [5, 7], to assess the response to GA
in RRMS over 2 years. The main findings in this study are
that the two established measures of lesions and atrophy,
T2LV and BPF, did not show a difference between GA and
an untreated group. However, the MRDSS was sensitive to a
group difference, which was driven by the scale’s inclusion
of a unique metric of the destructive potential of lesions, the
intrasubject T1/T2 ratio. These preliminary results under-
score the potential limitations of conventional MRI metrics
for longitudinal monitoring and show the potential utility of
a more comprehensive consideration of structural changes
that may relate to disease evolution, particularly the repre-
sentation of lesion destructive potential.
While the present study is the first to consider the use of
MRDSS or T1/T2 to monitor treatment response in MS, the
Table 2 MRI findings at baseline and 2-year follow-up
Glatiramer acetate NoDMT p value
Baseline
BPF 0.899 (0.808, 0.934) 0.878 (0.761, 0.950) 0.43
T2LV (ml) 2.57 (0.75, 9.31) 3.51 (1.00, 28.69) 0.29
T1/T2 0.24 (0.01, 0.91) 0.20 (0, 0.79) 1
-zBPF -1.24 (-1.88, 0.47) -0.84 (-2.18, 1.36) 0.43
zT2LV -0.79 (-2.26, 0.74) -0.42 (-1.91, 2.07) 0.29
zT1/T2 0.59 (-1.92, 3.11) 0.42 (-2.50, 2.39) 1
zMRDSS -1.55 (-4.35, 3.38) -0.78 (-4.15, 4.28) 0.46
Follow-up
BPF 0.888 (0.784, 0.936) 0.873 (0.754, 0.941) 0.54
T2LV (ml) 2.52 (0.62, 9.34) 2.83 (0.84, 26.67) 0.35
T1/T2 0.23 (0.02, 0.7) 0.33 (0.02, 0.98) 0.07
-zBPF -1.03 (-1.92, 0.93) -0.74 (-2.01, 1.49) 0.54
zT2LV -0.82 (-2.48, 0.74) -0.68 (-2.12, 1.99) 0.35
zT1/T2 0.55 (-1.41, 2.04) 0.91 (-1.41, 4.26) 0.07
zMRDSS -1.15 (-3.75, 2.62) -0.55 (-3.53, 5.64) 0.16
Key: median (range)
All p values are from Wilcoxon rank sum tests comparing the groups.
The negative zBPF is shown so that the direction matched the others (a
positive score indicates advancing disease). The MRDSS was calcu-
lated as a zMRDSS because the original scaling of the MRDSS to a
0–10 scale led to a MRDSS of[10 for a follow-up score
NoDMT not receiving disease-modifying therapy, BPF brain
parenchymal fraction, T2LV total cerebral T2 hyperintense lesion
volume, T1/T2 ratio of T1 hypointense to T2 hyperintense lesion
volume, MRDSS magnetic resonance disease severity scale,
z standardized
Table 3 MRI 2-year on-study changes
Glatiramer acetate p value NoDMT p value
-zBPF 0.12 (-0.18, 0.58) 0.001 0.10 (-1.47, 0.50) 0.002
zT2LV -0.03 (-0.90, 0.57) 0.26 0.01 (-1.69, 0.34) 0.95
zT1/T2 0 (-1.07, 1.20) 0.90 0.41 (-0.30, 2.51) 0.0002
zMRDSS 0.01 (-1.33, 1.28) 0.82 0.46 (-1.57, 2.46) 0.0006
Key: median (range)
All p values are from Wilcoxon signed rank tests assessing whether there was a significant change over 2 years for each measure within each
group. The negative zBPF is shown so that the direction matched the others (a positive score indicates advancing disease). The MRDSS was
calculated as a zMRDSS because the original scaling of the MRDSS to a 0–10 scale led to a MRDSS of[10 for a follow-up score
NoDMT not receiving disease-modifying therapy, BPF brain parenchymal fraction, T2LV total cerebral T2 hyperintense lesion volume, T1/T2
ratio of T1 hypointense to T2 hyperintense lesion volume, MRDSS magnetic resonance disease severity scale, z standardized
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Z4 composite score has been tested in the past. In a clinical
trial of roquinimex (linomide), the Z4 significantly distin-
guished the treatment groups at 3 months, and showed a
similar pattern between the groups at 6 months. In a study
evaluating the long term impact of GA therapy in a pla-
cebo-controlled cross-over trial, the Z4 discriminated
patients well according to duration of therapy and clinical
outcome [3]. In a placebo-controlled trial of anti-chlamy-
dial therapy in RRMS, the Z4 increased in the placebo
group and decreased in the antibiotic treatment group over
1 year [4]. These differences suggested a trend towards the
benefit of therapy and were driven by the stabilization in
the brain atrophy component of the scale. Unlike the Z4,
our MRDSS uses a novel measure of lesion severity, the
T1/T2 ratio, combined with overall burden of disease
(T2LV) and brain atrophy (BPF).
Prior work in developing the MRDSS has shown several
attractive features setting the stage for testing its sensitivity
in treatment monitoring [5, 7]. First, the MRDSS showed a
higher effect size in differentiating RR vs. SP MS pheno-
type groups when compared to the individual component
MRI measures [5]. Second, the MRDSS showed a higher
correlation with physical disability than what was seen
with conventional MRI lesion load [5]. Third, in a 3-year
longitudinal study, the MRDSS was more sensitive to
change in both RR and SP phenotype groups than the
individual component MRI measures [7]. Fourth, the
MRDSS showed the largest effect size in differentiating
cognitively preserved vs. cognitively impaired patients
with MS when compared to the individual component MRI
measures [10]. Finally, the standardization of measures that
is necessary to derive the MRDSS most likely improves the
clinical relevance [5]. The current results extend our pre-
vious observations in that the MRDSS detected a differ-
ence between treatment groups that was not apparent when
considering the established measures of conventional
lesion load or brain atrophy on their own. Taken together,
these exploratory findings underscore the potential advan-
tages of a comprehensive scale of MRI-defined disease
severity that considers several related but different aspects
of disease pathophysiology.
The MRDSS detected a group difference that was not
apparent by considering changes in either T2LV or BPF. It
Fig. 1 On-study brain atrophy in glatiramer acetate vs. untreated
patients. Mean (±standard error of the mean) of brain parenchymal
fraction (BPF) at baseline and 2-year follow-up. A lower score
indicates advancing disease. Both glatiramer acetate (GA) and no
disease modifying therapy (noDMT) cohorts showed significant
decreases in BPF (i.e. no brain atrophy) from baseline to follow-up.
The p values in the figure are from Wilcoxon signed rank tests for the
within group change over time. Furthermore, when comparing the
change in zBPF between the two groups, no difference was found
(Wilcoxon rank sum test, p = 0.59)
Fig. 2 On-study T2 hyperintense lesion volume changes in glati-
ramer acetate vs. untreated patients. Mean (±standard error of the
mean) of total cerebral T2 hyperintense lesion volume (T2LV) at
baseline and 2-year follow-up. A higher score indicates advancing
disease. Both glatiramer acetate (GA) and no disease modifying
therapy (noDMT) cohorts showed no significant decreases from
baseline to follow-up. The p values in the figure are from Wilcoxon
signed rank tests for the within group change over time. Furthermore,
when comparing the change in zT2LV between the two groups, no
difference was found (Wilcoxon rank sum test, p = 0.40)
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was clear from examination of the data, that the group
difference in MRDSS, suggesting a treatment effect of GA,
was dominated by changes in the T1/T2. This is the
intrasubject ratio of the volume of cerebral T1 hypointense
to T2 hyperintense lesions. This ratio roughly equates to an
index of the destructive potential of a patient’s lesions in
that it is well known that chronic T1 hypointensity indi-
cates severe destructive pathology (severe irreversible
demyelination and axonal loss) [23–25]. Given that the
scale is derived from a single time point scan, the
chronicity of T1 hypointensity is not assured. But, the
exclusion of Gd-enhancing lesions from our definition of
T1 hypointense lesions reduced the likelihood of including
transient/benign T1 hypointense lesions [26]. Furthermore,
the high clinical relevance of the T1/T2 has been suggested
by several previous studies. One study showed a higher T1/
T2 in SP vs. RR MS, with higher effect sizes than T2LV or
BPF differences [5]. In a 3-year longitudinal study, the T1/
T2 was more sensitive to change in both RR and SP phe-
notype groups than T2LV or BPF [7]. In addition, the T1/
T2 showed a larger effect size in differentiating cognitively
preserved vs. cognitively impaired patients with MS when
compared to T2LV [10]. The T1/T2 shows only moderate
correlations with either T2LV or BPF [5], indicating its
ability to detect divergent aspects of disease severity. The
pathobiologic factors contributing to the tendency towards
more destructive lesions in MS patients are unknown. One
line of investigation relates to genetic predisposition [27,
28]. There is a relatively low co-linearity between T1/T2
and either T1LV, T2LV, or BPF [5]. Taken together, these
observations suggest the unique role of the information
provided by T1/T2 that may complement the evaluation of
cerebral disease severity obtained by standard evaluations
of lesion load and atrophy.
There are several lines of evidence regarding the effect of
GA therapy in MS that may help to explain the selective
effect on T1 hypointense-associated lesion characteristics
suggested in this pilot study. While most of the available
DMTs for MS act by reducing lymphocyte entry into the
CNS, GA is thought to have a unique mechanism of action
[29, 30]. Animalmodel and clinical studies show the effect of
GA on shifting pro-inflammatory to anti-inflammatory
immune actions [29, 30]. In addition to immunomodulatory
effects, the drug may also promote the secretion of
Fig. 3 On-study T1/T2 ratio changes in glatiramer acetate vs.
untreated patients. Mean (±standard error of the mean) of the ratio
of total cerebral T1 hypointense to T2 hyperintense lesion volume
(T1/T2) at baseline and 2-year follow-up. A higher score indicates
advancing disease. The no disease modifying therapy (noDMT) group
showed significant worsening, but the glatiramer acetate (GA) treated
group did not. The p values in the figure are from Wilcoxon signed
rank tests for the within group change over time. Furthermore, when
comparing the change in zT1/T2 between groups, a difference was
found favoring GA treatment (Wilcoxon rank sum test, p = 0.003)
Fig. 4 On-study MRDSS changes in glatiramer acetate vs. untreated
patients. Mean (±standard error of the mean) of the magnetic
resonance disease severity scale (zMRDSS) at baseline and 2-year
follow-up. A higher score indicates advancing disease. The no disease
modifying therapy (noDMT) group showed significant worsening, but
the glatiramer acetate (GA) treated group did not. The p values in the
figure are from Wilcoxon signed rank tests for the within group
change over time. Furthermore, when comparing the change in
zMRDSS between groups, a difference was found favoring GA
treatment (Wilcoxon rank sum test, p = 0.01)
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neurotrophins to enhance repair processes and remyelination
[29]. Consistent with this hypothesis, a placebo-controlled
phase III clinical trial showed that the percentage of new
cerebral lesions evolving into chronic T1 hypointensities
was lower in GA-treated vs. placebo-treated RRMS patients
[18]. Such a treatment effect of GA has been confirmed in
subsequent studies of different patient populations [31, 32].
In the present study, when comparing the change in zT1/T2
between groups, a significant difference was found favoring
GA treatment vs. no treatment. This was the result of a sig-
nificant increase in the T1/T2 in untreated patients but no
change in GA patients over 2 years. Taken together, while
preliminary and requiring confirmation in larger studies,
these results suggest that GA can limit tissue destruction in
lesions once they have formed leading to a reduced level of
long term tissue injury.
In the present study, the GA and untreated groups did not
differ on their rates of changes inT2LVorBPFover the 2-year
observation period. This is in contrast to the results of large
phase III placebo-controlled studies, inwhichGA reduced the
rate of progression of T2LV in RRMS [14] or clinically-iso-
lated demyelinating syndromes [33]. Our study, given the
much smaller sample size and retrospective study design,may
have been under-powered to show such effects. Regarding the
effect of GA on limiting brain atrophy, results have been
inconsistent [34], showing either a partial delayed effect [17,
35] or no effect [33, 36] in the above-referenced phase III
studies. Furthermore, the sensitivity of brain atrophy as a
longitudinalmonitoring tool in the evaluation ofMS therapies
has been hampered by several factors [37, 38]. The limitations
include the delayed effect of newly started DMT on atrophy
(usually requiring a lag time of several months to a year), the
partial effect (amaximumbenefit of up to 40–50 %per year in
the rate of reduction), and the confounding effects on brain
volume of acute DMT-related or corticosteroid brain volume
change (i.e. pseudoatrophy due to anti-inflammatory effects
and fluid shifts) [37, 38]. Furthermore, other unexpected
factors may alter brain volume measurements such as diurnal
fluctuations [39]. Taken together, the above observations
suggest it is perhaps not surprising that our study failed to
detect any difference inT2LVorBPFchange between the two
groups in this small study.
Our study was not without several limitations. This work
was exploratory and the findings should be considered pre-
liminary. The ‘‘real world’’ subject groups may have been
biased due to the retrospective study design and non-ran-
domized treatment assignment. The groups were not ideally
matched at study entry on male/female ratio, age, disease
duration, and disability. This may have affected the results in
that, for example, the higher disability, higher percentage of
men, and lower disease duration at entry in the GA group
may have led to a bias. Future studies should be properly
designed to provide more definitive results which would
allow extension and confirmation of our observations. Post-
hoc analyses of phase III trial data would be particularly
helpful to overcome several of these limitations. Advanced
MRI techniques may prove more specific for use at a single
time point in the identification of themost destructive lesions
rather than relying on the volume of hypointensity on T1-
weighted images [26, 40]. Finally, to better understand the
full breadth of any potential treatment effects ofGA, it would
be of interest to incorporateMRImeasures of graymatter and
spinal cord pathology. Both of these aspects of disease
severity have shown a benefit in improving the validity of
MS-MRI composite scales [10, 11].
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